Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

139.15 +2.44 (+1.78%)

Streaming Delayed Price Updated: 9:45 AM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End ↗

April 20, 2022

Miguel Martin, CEO of Aurora Cannabis Inc (NASDAQ: ACB), discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday.

Via Benzinga

Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent ↗

April 19, 2022

The company agreed to the FDA's post-marketing requirements for a depression drug.

Via Investor's Business Daily

Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal ↗

April 13, 2022

Via Benzinga

Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies ↗

April 11, 2022

Syros Pharmaceuticals Inc (NASDAQ: SYRS)

Via Benzinga

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma ↗

April 07, 2022

Via Benzinga

Expert Ratings For Jazz Pharmaceuticals ↗

April 06, 2022

Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

April 06, 2022

Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading.

Via Benzinga

Why Axsome Therapeutics Stock Is Trading Higher ↗

March 28, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ).

Via Benzinga

Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio ↗

March 28, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) has

Via Benzinga

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗

March 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Jazz Pharmaceuticals's Return On Capital Employed Insights ↗

March 03, 2022

According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company...

Via Benzinga

Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma ↗

March 03, 2022

The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant C...

Via Benzinga

Expert Ratings For Jazz Pharmaceuticals ↗

March 02, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results ↗

March 01, 2022

Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharma...

Via Benzinga

Jazz Pharmaceuticals: Q4 Earnings Insights ↗

March 01, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

This Company's 18-Month CBD Stability Achievement Could Hint Towards Expansion Goals As It Plans To Release First Commercial UST System In 2022 ↗

February 10, 2022

Photo by Kindel Media from Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Does This Company's Recent CBD Breakthrough Earn It A Spot In The Guinness World Records? ↗

February 04, 2022

Photo by CBD Infos on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

The "Cannabis 50" List For 2021 Is Out, Is Your Favorite Company On It? ↗

January 28, 2022

MGO (Macias Gini and O’Connell LLP), a leader in accounting, tax, audit and advisory solutions for the cannabis and hemp industries has released its 3rd annual “Cannabis 50” list.

Via Benzinga

Jim Cramer Shares His Thoughts On ArcBest, Ulta Beauty And More ↗

January 27, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes ArcBest Corporation (NASDAQ:

Via Benzinga

Zogenix Nabs $1.9 Billion Takeover As Epilepsy Drug Piques UCB Interest ↗

January 19, 2022

The deal includes a CVS tied to Fintepla's next potential approval.

Via Investor's Business Daily

Report: Global Cannabis Beverages Market Expected To Reach $2B By 2026 ↗

January 14, 2022

As the COVID-19 pandemic continues, the global market for cannabis beverages estimated at $799.8 million 2020, is projected to reach a revised...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)

January 06, 2022

Via AB Newswire

A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report ↗

January 04, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year....

Via Benzinga

5 Stocks To Watch For January 4, 2022 ↗

January 04, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.